Literature DB >> 11733259

Mycobacterium interface keratitis after laser in situ keratomileusis.

A Solomon1, C L Karp, D Miller, S R Dubovy, A J Huang, W W Culbertson.   

Abstract

PURPOSE: To report the clinical course, management, and outcome of infectious interface keratitis caused by mycobacterium species after laser in situ keratomileusis (LASIK).
DESIGN: A small noncomparative interventional case series. PARTICIPANTS: Five eyes in four patients who underwent LASIK in different locations around the world and had culture-positive mycobacterium keratitis develop. INTERVENTION: The LASIK flap was lifted or amputated, samples were submitted for Ziehl-Neelsen acid-fast stain and Lowenstein-Jensen's agar cultures for diagnosis; topical treatment with fortified clarithromycin and amikacin was administered until clinical resolution. MAIN OUTCOME MEASURES: Time periods from onset to diagnosis and from diagnosis to clinical resolution, and the final visual acuity.
RESULTS: Onset of symptoms of infection occurred after a mean of 20 days (range, 11 days-6 weeks) after LASIK or an enhancement procedure. Definitive diagnosis was obtained after a mean period of 4.5 weeks (range, 12 days-8 weeks) from onset. Keratitis resolved within 8.4 weeks (range, 1-18 weeks) of treatment with fortified clarithromycin and amikacin. Corticosteroids were found to worsen and prolong the course of disease. In four of five eyes the LASIK flap was amputated.
CONCLUSIONS: Mycobacterial keratitis is a potentially vision-threatening complication after LASIK, characterized by a long latent period, delayed diagnosis, and a protracted course even under intensive specific antibiotic therapy. Inclusion of specific culture media and staining protocols for mycobacteria, along with aggressive treatment on diagnosis, including lifting or amputating the LASIK flap, culturing, topical fortified clarithromycin and amikacin, while avoiding corticosteroids, may significantly improve resolution of the infection and potentially improve the visual outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733259     DOI: 10.1016/s0161-6420(01)00851-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

Review 1.  [Diagnosis and treatment of mycobacterial keratitis following LASIK. Case report and review of the literature].

Authors:  M P Holzer; K D Solomon; H P Sandoval; G U Auffarth
Journal:  Ophthalmologe       Date:  2003-06-26       Impact factor: 1.059

Review 2.  Nontuberculous Mycobacterial Ocular Infections: A Systematic Review of the Literature.

Authors:  Wajiha J Kheir; Huda Sheheitli; Maamoun Abdul Fattah; Rola N Hamam
Journal:  Biomed Res Int       Date:  2015-05-27       Impact factor: 3.411

3.  Nasal and conjunctival screening prior to refractive surgery: an observational and cross-sectional study.

Authors:  Koji Kitazawa; Chie Sotozono; Masako Sakamoto; Miho Sasaki; Osamu Hieda; Toshihide Yamasaki; Shigeru Kinoshita
Journal:  BMJ Open       Date:  2016-05-09       Impact factor: 2.692

4.  Biofilms of Pathogenic Nontuberculous Mycobacteria Targeted by New Therapeutic Approaches.

Authors:  Thet Tun Aung; Joey Kuok Hoong Yam; Shuimu Lin; Shuhaida Mohamed Salleh; Michael Givskov; Shouping Liu; Nyein Chan Lwin; Liang Yang; Roger W Beuerman
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

Review 5.  Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review.

Authors:  JaeSang Ko; Se Kyung Kim; Dong Eun Yong; Tae-Im Kim; Eung Kweon Kim
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

6.  Traumatic laser in situ keratomileusis flap dislocation with epithelial ingrowth, Propionibacterium acnes infection, and diffuse lamellar keratitis: A case report.

Authors:  Yung-Ching Chang; Yuan-Chieh Lee
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.889

Review 7.  Treatment-Resistant Bacterial Keratitis: Challenges and Solutions.

Authors:  Sait Egrilmez; Şeyda Yildirim-Theveny
Journal:  Clin Ophthalmol       Date:  2020-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.